Comparison · NCT01041274-sae
Citalopram vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Citalopram vs Placebo: serious adverse events. Trial comparisons, record NCT01041274-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01041274-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.102 | 0.0444 | 0.218 | wilson | |
| Risk in group 2 | 0.087 | 0.0343 | 0.203 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0151 | -0.115 | 0.142 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.17 | 0.336 | 4.1 | log | |
| Odds ratio, group 1 over group 2 | 1.19 | 0.3 | 4.75 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Citalopram than on Placebo | 66.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Citalopram | Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.~Citalopram: 40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily. | 5 | 49 | EG000 |
| Group 2 | Placebo | Participants will receive a daily dose of placebo for 12 months.~Placebo: Placebo by mouth daily for 12 months.~Psychoeducation: 16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions~Cognitive Behavioral Therapy (CBT): Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI~Functional Magnetic Resonance Imaging (fMRI): 3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52 | 4 | 46 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- DECIFER: Depression and Citalopram In First Episode Recovery
- NCT number
- NCT01041274
- Phases
- PHASE4
- Conditions
- Schizophrenia, Schizophreniform Disorder
- Interventions
- Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
- Lead sponsor
- NYU Langone Health
- Results first posted
- 2018-11-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01041274?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01041274-sae